Ava Fertility Tracking Bracelet Now Available as a Family-building Benefit Support Tool Through Partnership with WINFertility
ZURICH, SWITZERLAND — November 4, 2021 — Ava, maker of the first FDA-cleared fertility tracking wearable, announced today it will now be available as a workplace family-building benefit support tool through a partnership with WINFertility (WIN), the nation’s leading fertility benefits management company with the largest portfolio of employer clients. The partnership will allow WIN to make the Ava bracelet available to its members, providing an alternate pathway to access data-driven technology that increases the chances of natural conception.
“Our partnership with WIN enables us to meet women earlier in the family-building journey,” said Ava CEO Lea von Bidder. “Ava gives them something proactive they can do to increase their chances of natural conception from day one.”
The Ava bracelet is an ovulation tracking device that uses sensor technology and artificial intelligence to detect a woman’s most fertile days. Ava’s technology will support WINFertility employer group members with key insights to help them get pregnant faster.
One in eight couples in America has difficulty becoming pregnant. And each infertility patient in the United States undergoes 2.5 cycles of IVF on average, which costs between $40,000 and $50,000. The Ava bracelet is a clinically proven fertility support tool that, like WINFertility, can help couples conceive naturally and employers reduce costs associated with the family-building journey.
“Our partnership with Ava is an important opportunity for WIN to further assist a broader set of patients earlier in their journey to parenthood,” said Peter Nieves, Chief Commercial Officer of WINFertility. “Employers are seeking ways to support their employees' desire to start and build their families with new and innovative tools and procedures.”
Employers interested in including Ava in their corporate benefit offering can visit http://www.winfertility.com for more information.
About Ava
Ava is a digital health company with offices in Zurich, San Francisco, Belgrade, and Makati that advances women’s reproductive health by bringing together artificial intelligence and clinical research. Launched in 2016, Ava Fertility has a large, happy user base, clinical validation in multiple clinical trials, and regulatory validation through its FDA and European clearances. Studies for the clinical use of Ava have been conducted in collaboration with academic partners around the world, including at the University Hospital of Zurich, Switzerland, Columbia University, and Northwestern University’s Feinberg School of Medicine. Ava was voted Best of Baby Tech at CES, named a Women’s Health “Editors’ Choice” product and has been honored as a CB Insights Digital Health 150 company. For more information on Ava, visit www.avawomen.com.
About WINFertility
WINFertility is the nation’s leading family-building and fertility benefit management company, providing comprehensive solutions for employers, health plans and consumers. From fertility management, including medical treatment, pharmacy and genetics to surrogacy and adoption, WINFertility has helped more than 150,000 families by providing access to the best doctors, technology, and support. WIN works with the nation’s leading reproductive endocrinologists and integrates with national and regional insurance carriers, as well as the nation’s largest pharmacy benefit managers, to deliver the most advanced and effective fertility treatments and family-building solutions. WIN Nurse Care Managers navigate patients through the often complex process, providing clinical oversight, emotional support, advocacy, and education throughout the journey. Patients and clients that utilize WIN’s program see higher pregnancy rates, fewer multiple gestations, more efficient Rx utilization, and lower costs. The company headquarters are based in Greenwich, CT.